Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …

Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

Ruthenium complex is an important compound group for antitumor drug research and
development. NAMI-A, KP1019, TLD1433 and other ruthenium complexes have entered …

Introduction Advanced breast cancer (aBC) remains incurable and the quest for more
effective systemic anticancer agents continues. Promising results have led to the FDA …

Mesenchymal stem cells (MSCs), one of the most common types of stem cells, are involved
in the modulation of the tumor microenvironment (TME). With the advancement of …

Over the past two decades, cancer treatment has benefited from having a significant
increase in the number of targeted drugs approved by the United States Food and Drug …

• New systemic anticancer treatments, such as targeted therapy and immunotherapy, have
made treating incurable solid cancer more successful but also more challenging and …

Systemic drug delivery is the current clinically preferred route for cancer therapy. However,
challenges associated with tumor localization and off-tumor toxic effects limit the clinical …

Background This study compares the safety and efficacy of first‐line treatments for
anaplastic lymphoma kinase (ALK)‐mutated non–small cell lung cancer (NSCLC). Methods …

Introduction Breast cancer (BC) is the most common type of cancer diagnosed among
women worldwide with an estimated 2.3 million new cases every year. Almost two-thirds of …